No Survival Benefit of Percutaneous Revascularization for Ischemic LV Dysfunction

In the REVIVED trial, survival, hospitalization, and left ventricular systolic function were no better with an invasive than a conservative strategy during intermediate-term follow-up.

Questions remain about optimal management for patients with coronary artery disease (CAD) and severe, ischemic left ventricular (LV) systolic dysfunction, who were excluded from the ISCHEMIA trial (NEJM JW Cardiol May 2020 and N Engl J Med 2020; 382:1395). In the REVIVED-BCIS2 trial (NCT01920048), conducted at 40 U.K. centers, investigators randomized 700 patients (mean age, 70 years; 88% male; 91% white) with LV ejection fractions (LVEFs) ≤35%, extensive CAD, and demonstrable viability (without acute myocardial infarction in the prior 4 weeks) to receive percutaneous coronary intervention (PCI) plus optimal medical therapy or medical therapy alone. PCI required attempt of revascularization of all diseased proximal coronary vessels subtendi…

Reviewing Author

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy

No Survival Benefit of Percutaneous Revascularization for Ischemic LV Dysfunction

Topics

Reviewing Author